Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series

International Journal of Neuroscience

Volumn 126, Issue 11, 2016, Pages 1002-1006

  Alanin, Mikkel Christian ^a   Klausen, Camilla ^a   Caye Thomasen, Per ^a,b   Thomsen, Carsten ^a,b   Fugleholm, Kaare ^a   Poulsgaard, Lars ^a   Lassen, Ulrik ^a   Mau Sorensen, Morten ^a   Hofland, Kenneth Francis ^a  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

avastin; bevacizumab; Macdonald criteria; meningiomas; neurofibromatosis; VEGF

Indexed keywords

BEVACIZUMAB; CONTRAST MEDIUM; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INTRACRANIAL MENINGIOMA; INTRACRANIAL TUMOR; MACDONALD CRITERIA; MALE; MENINGIOMA; MIDDLE AGED; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TREATMENT DURATION; YOUNG ADULT; COMPLICATION; DIAGNOSTIC IMAGING; MENINGEAL NEOPLASMS; OUTCOME ASSESSMENT;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEUROFIBROMATOSIS 2; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84945242447     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1092443     Document Type: Article

References (17)

1. D.G.Evans Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
2. W.J.Sherman, J.J.Raizer. Chemotherapy: what is its role in meningioma? Expert Rev Neurother 2012;12:1189–95.
3. L.Rogers, I.Barani, M.Chamberlain, Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122:4–23.
4. S.R.Plotkin, A.O.Stemmer-Rachamimov, F.G.Barker, Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–67.
5. F.P.Nunes, V.L.Merker, D.Jennings, Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013;8:e59941 (Epub ahead of print).
6. M.C.Alanin, C.Klausen, P.Caye-Thomasen, The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2014. doi:10.1007/s00405-014-3398-3
7. E.Lou, A.L.Sumrall, S.Turner, Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012;109:63–70.
8. L.Nayak, F.M.Iwamoto, J.D.Rudnick, Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012;109:187–93.
9. D.G.Evans, S.M.Huson, D.Donnai, A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603–18.
10. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11–13, 1991. The Consensus Development Panel. Arch Neurol 1994;51:201–7.
11. D.R.Macdonald, T.L.Cascino, S.C.Schold, Jr., J.G.Cairncross. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
12. A.H.Hawasli, J.B.Rubin, D.D.Tran, Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013;74:136–41.
13. S.Goutagny, E.Raymond, O.Sterkers, Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011;22:990–1.
14. L.A.Zeidman, W.J.Ankenbrandt, H.Du, Growth rate of non-operated meningiomas. J Neurol 2008;255:891–5.
15. E.Dombi, S.L.Ardern-Holmes, D.Babovic-Vuksanovic, Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013;81:S33–40.
16. S.R.Plotkin, V.L.Merker, C.Halpin, Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurootol 2012;33:1046–52.
17. V.F.Mautner, R.Nguyen, H.Kutta, Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncology 2010;12:14–8.